Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused pandemic since outbreak in 2020. Patients with cancers may be at higher risk than those without cancer for coronavirus disease 2019 (COVID-19). At present, limited data are available on the safety and immunogenicity of COVID-19 vaccination for patients with cancer.
This study is a prospective, single-arm, open-label clinical trial. A total of 300 patients with different cancers including hepatocellular carcinoma, breast cancer, lung cancer, esophageal cancer, gastric cancer and colorectal cancer were included in this vaccination study. All of the patients will further accept 12 months follow-up study after vaccination. Safety and immunogenicity will be carefully recorded and detected.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
300
Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China
RECRUITINGSafety of coronavirus vaccine
Occurence of adverse effects after COVID-19 vaccination
Time frame: Within 2 months after the first dose of coronavirus vaccine
Immunogenicity of coronavirus vaccine
Titers of anti-SARS-CoV-2 antibodies
Time frame: Within 2 months after the first dose of coronavirus vaccine
Safety of coronavirus vaccine
Occurence of adverse effects after COVID-19 vaccination
Time frame: Within 13 months after the first dose of coronavirus vaccine
Immunogenicity of coronavirus vaccine
Titers of anti-SARS-CoV-2 antibodies
Time frame: Within 13 months after the first dose of coronavirus vaccine
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.